MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$21,258K
Free Cash flow
-$62,998K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable debt se...
Net loss
Proceeds from sales of common st...
Others
Negative Cash Flow Breakdown
Accounts receivable
Accounts payable
Deferred revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
-
-133,711
-
140,104
Cost of license and royalty revenues
-
-3,296
-
14,370
Total research and development expense
-
-111,349
-
168,688
Total general and administrative expense
-
-39,177
-
60,483
Other segment items
-
-16,567
-
23,292
Net loss
22,709
-90,051
-67,149
-61,941
Stock-based compensation expense
9,053
8,617
8,375
8,998
Depreciation and amortization
3,757
3,857
3,869
3,886
Net accretion of discounts on marketable debt securities
442
879
1,229
1,823
Net realized gain on investments
16
-
0
62
Non-cash interest expense
5,987
3,753
5,106
5,305
Other non-cash adjustments
5
-19
-537
-48
Accounts receivable
96,714
-18,249
561
6,310
Prepaid expenses
361
-384
-1,016
2,167
Other current assets
-2,286
1,314
-6,244
-7
Operating lease right-of-use assets
-1,674
-1,705
-1,664
-1,683
Other assets
389
900
345
2,389
Accounts payable
-5,288
349
-1,861
694
Accrued expenses and other current liabilities
1,171
-16,734
45
2,751
Deferred revenue
-3,409
-700
-4,986
-3,400
Operating lease liabilities
-2,115
-2,525
-3,005
-1,224
Other liabilities
-136
-16
-10
-16
Net cash used in operating activities
-62,238
-76,186
-52,290
-55,960
Purchases of marketable debt securities
0
9,839
62,811
39,521
Maturities of marketable debt securities
55,220
81,662
100,857
82,237
Sales of equity securities
-
-
0
62
Sales of marketable debt securities
11,465
-
-
-
Purchases of property and equipment
760
1,235
508
491
Net cash provided by (used in) investing activities
65,925
70,588
37,538
42,287
Proceeds from exercise of stock options
51
146
90
0
Taxes paid related to net settlement of stock-based awards
0
828
0
123
Proceeds from issuance of common stock under employee stock purchase plan
0
648
0
741
Proceeds from sales of common stock under at-the-market offering program, net of commissions
19,499
-
-
-
Offering expenses related to at-the-market offering program
-
-
-
75
Expenses related to at-the-market offering program
173
230
357
-
Proceeds from issuance of royalty bond and warrants, net of transaction costs
-
-
0
-33
Repayments under royalty monetization liabilities, net of interest
1,806
13,375
9,651
7,593
Net cash provided by financing activities
17,571
-13,639
-9,584
-7,083
Net increase in cash and cash equivalents and restricted cash
21,258
-19,237
-24,336
-20,756
Beginning of period
17,259
36,496
60,832
59,556
End of period
38,517
17,259
36,496
60,832
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
debt securities
$55,220K
(-59.40%↓ Y/Y)
Sales of marketable
debt securities
$11,465K
Proceeds from sales of
common stock under...
$19,499K
Proceeds from exercise of
stock options
$51K
(-77.63%↓ Y/Y)
Net cash provided by
(used in) investing...
$65,925K
(168.89%↑ Y/Y)
Net cash provided by
financing activities
$17,571K
(-86.83%↓ Y/Y)
Canceled cashflow
$760K
Canceled cashflow
$1,979K
Net increase in cash
and cash...
$21,258K
(-3.51%↓ Y/Y)
Canceled cashflow
$62,238K
Purchases of property and
equipment
$760K
(-46.29%↓ Y/Y)
Net loss
$22,709K
(135.05%↑ Y/Y)
Stock-based compensation
expense
$9,053K
(-47.34%↓ Y/Y)
Non-cash interest
expense
$5,987K
(140.44%↑ Y/Y)
Depreciation and
amortization
$3,757K
(-52.20%↓ Y/Y)
Other current assets
-$2,286K
(-140.87%↓ Y/Y)
Operating lease
right-of-use assets
-$1,674K
(49.36%↑ Y/Y)
Accrued expenses and
other current...
$1,171K
(145.62%↑ Y/Y)
Repayments under royalty
monetization liabilities,...
$1,806K
(-83.36%↓ Y/Y)
Expenses related to
at-the-market offering...
$173K
Net cash used in
operating activities
-$62,238K
(-296.09%↓ Y/Y)
Canceled cashflow
$46,637K
Accounts receivable
$96,714K
(12142.28%↑ Y/Y)
Accounts payable
-$5,288K
(-373.41%↓ Y/Y)
Deferred revenue
-$3,409K
(-109.05%↓ Y/Y)
Operating lease
liabilities
-$2,115K
(51.89%↑ Y/Y)
Net accretion of
discounts on marketable...
$442K
(-81.79%↓ Y/Y)
Other assets
$389K
(118.34%↑ Y/Y)
Prepaid expenses
$361K
(-78.88%↓ Y/Y)
Other liabilities
-$136K
(95.42%↑ Y/Y)
Net realized gain on
investments
$16K
Other non-cash
adjustments
$5K
(141.67%↑ Y/Y)
Buy us a coffee
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)